Bristol Myers Squibb Signs US$15.2 B Licensing Pact with Hengrui Pharma for Medicines Across Oncology, Haematology, and Immunology

By Sanya Sekhri

Pharma Deals Review: Vol 2026 Issue 5 (Table of Contents)

Published: 20 May-2026

DOI: 10.3833/pdr.v2026.i5.3017     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

In one of the largest partnerships of 2026 so far, Bristol Myers Squibb (BMS) has signed a licensing agreement with Hengrui Pharma to develop a portfolio of 13 early-stage programmes in oncology, haematology, and immunology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details